Cas:590398-05-3 2-tert-butyl-1H-benzo[g]indole-3-carbaldehyde manufacturer & supplier

Chemical Name:2-tert-butyl-1H-benzo[g]indole-3-carbaldehyde

CAS.NO:590398-05-3

Synonyms:2-(tert-butyl)-1h-benzo[g]indole-3-carboxaldehyde

Molecular Formula:C₁₇H₁₇NO

Molecular Weight:251.32300

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:32.86000

Exact Mass:251.13100

LogP:4.43110

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 2-(tert-butyl)-1h-benzo[g]indole-3-carboxaldehyde chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-(tert-butyl)-1h-benzo[g]indole-3-carboxaldehyde physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-(tert-butyl)-1h-benzo[g]indole-3-carboxaldehyde Use and application,2-(tert-butyl)-1h-benzo[g]indole-3-carboxaldehyde technical grade,usp/ep/jp grade.

Related News: Chinese officials on Sunday reported a surge in new cases. 2-tert-butyl-1H-benzo[g]indole-3-carbaldehyde manufacturer The FDA also said that the labeling of the diagnostic, which comes in different versions, included performance claims that did not match up with results seen in clinical studies—and that the data Innova submitted for review “was identical to data previously provided by other manufacturers” in separate requests for emergency COVID authorizations, raising additional questions. 2-tert-butyl-1H-benzo[g]indole-3-carbaldehyde supplier The active ingredient (AI) is the substance or substances that are biologically active within the drug and is the specific component responsible for the desired effect it has on the individual taking it. 2-tert-butyl-1H-benzo[g]indole-3-carbaldehyde vendor We also have to consider the degree of concentration and which temperature allows a high quality of API to be manufactured efficiently. 2-tert-butyl-1H-benzo[g]indole-3-carbaldehyde factory The FDA also said that the labeling of the diagnostic, which comes in different versions, included performance claims that did not match up with results seen in clinical studies—and that the data Innova submitted for review “was identical to data previously provided by other manufacturers” in separate requests for emergency COVID authorizations, raising additional questions.